Table 1

patient characteristics

Patient nrGenderAgePrior treatmentsMetastatic sitesLocation for tumor resectionPerformance status
1M67DTIC, ipilimumabLung, adrenal, subcutaneousSubcutaneous0
2M68DTIC, DC vaccination, ipilimumabLung, LN, spleen, subcutaneousLN0
3M46Vemurafenib, ipilimumabLN, subcutaneousSubcutaneous0
4F44DTIC, vemurafenib, ipilimumabLN, subcutaneous, soft tissueSubcutaneous0
5F40DTIC, ipilimumabLung, subcutaneous, soft tissueSubcutaneous0
6F43Temozolamide, IFN-α, DC vaccination,LN, long, subcutaneousAxillary LN0
Ipilimumab, vemurafenib
7M52DTIC, ipilimumabLN, lung, subcutaneousLN0
8M40Peptide vaccination, ipilimumabLN, small intestineLarge intestine0
Mesoduodenum
9F60Vemurafenib, DTIC, ipilimumabLN, subcutaneousLN1
10M55DC vaccination, ipilimumabLN, subcutaneous, liver, lungJejunum1
  • DC, dendritic cell; DTIC, dacarbazine; IFN-α, interferon-α; LN, lymph node.